Dr. Lal Pathlabs Ltd. News and Updates

Name: Latest research reports of Dr. Lal Pathlabs Ltd. authored by Geojit BNP Paribas and published by - Trendlyne research reports.
Item: Dr. Lal Pathlabs Ltd.
Rating: 4
Author: Geojit BNP Paribas

Keep track of all breaking news on Dr. Lal Pathlabs Ltd. from all sources in a single place.

Load latest

Dr. Lal Pathlabs Ltd.

18 Feb 2022

2807.80

1.79%

Covid-19 pandemic: Mizoram reports 1,571 new cases and one death

Business Standard

Mizoram reported 1,571 new COVID-19 cases on Thursday, 45 less than the previous day, taking the state's tally to 2,02,206, an official said. The death toll rose to 640 with a six-year-old girl from Aizawl succumbing to the infection at Zoram Medical College (ZMC), he said. As many as1,871 people have recovered from the disease in the last 24 hours, taking the total recoveries to 1,92,093. The recovery rate among COVID-19 patients is 95 per cent and the death rate is 0.31 per cent, he said. The single-day positivity rate increased to 25.83 per cent from 23.56 per cent on the previous day, the official said. The northeastern state now has 9,473 active COVID-19 cases. Mizora has so far tested more than 17.78 lakh samples for COVID-19. According to state immunisation officer Dr. Lalmuanawma Jongte, over 8 lakh people have been inoculated till Wednesday and 6.40 lakh of them have been fully vaccinated.

Dr. Lal Pathlabs Ltd. is trading below its 150 day SMA of 2891.9

Dr. Lal Pathlabs Ltd.

16 Feb 2022

2807.80

1.79%

DR. LAL PATHLABS LIMITED

Accumulate: Dr. Lal Pathlabs Ltd.

Target

Geojit BNP Paribas

Dr. Lal PathLabs Limited (DLPL) provides diagnostic and related healthcare tests and services in India and internationally. Company has 231 clinical laboratories, including National Reference Lab at Delhi and Regional...

Dr. Lal Pathlabs Ltd. is trading above its 100 day SMA of 2744.2

Dr. Lal Pathlabs Ltd.

11 Feb 2022

2807.80

1.79%

Dr Lal PathLabs' Q3 performance hit by acquisition cost

livemint

Analysts say the acquisition of Suburban Diagnostics was important from a long-term perspective of making Dr Lal PathLabs a pan-India company, and the company may prefer to gain scale over improving margins at this stage

Dr. Lal Pathlabs Ltd. is trading below its 150 day SMA of 2891.9

Diagnostics chain Dr Lal PathLabs posts Rs 58 crore profit for Dec quarter

Business Standard | 10 Feb 2022

Dr. Lal Pathlabs Ltd.

11 Feb 2022

2807.80

1.79%

Dr Lal PathLab Standalone December 2021 Net Sales at Rs 422.50 crore, down 1.08% Y-o-Y

Moneycontrol

NULL

Emkay increased Buy price target of Dr. Lal Pathlabs Ltd. to 3100.0 on 26 Apr, 2025.

Dr. Lal Pathlabs Ltd.

10 Feb 2022

2807.80

1.79%

Earnings Call for Q3FY22 of Dr. Lal Pathlabs

Conference Call with Dr. Lal Pathlabs Management and Analysts on Q3FY22 Performance and Outlook. Listen to the full earnings transcript.

audio

Dr. Lal Pathlabs Ltd.

10 Feb 2022

2807.80

1.79%

to see Rapid results content

Dr. Lal Pathlabs Ltd.

13 Jan 2022

2807.80

1.79%

LIC picks up stake in this healthcare stock in December quarter

livemint

LIC has bought 1.12% stake in Dr Lal PathLabs during the October-December 2021 period, BSE data showed

Dr. Lal Pathlabs Ltd. is trading above its 100 day SMA of 2744.2

Dr. Lal Pathlabs Ltd.

15 Nov 2021

2807.80

1.79%

Network effects

Business Standard

It is a pleasure to read Dr Lally's engagements with the economy of this far-flung overland trade, furnishing serialised and tabular data

Dr. Lal Pathlabs Ltd. is trading above its 100 day SMA of 2744.2

Dr. Lal Pathlabs Ltd.

28 Oct 2021

2807.80

1.79%

to see Rapid results content

Dr. Lal Pathlabs Ltd.

28 Oct 2021

2807.80

1.79%

Lal PathLabs can fortify its hold if suburban is integrated well

Economic Times

Dr Lal PathLabs (LPL), India's largest diagnostics player by revenue and presence, is slated to become bigger with the acquisition of Suburban Diagnostics, which has a sizable presence in western India. At the total deal value of Rs 1,150 crore, LPL valued Sequoia Capital-backed Suburban at nearly four times its FY21 revenue.